Clene (NASDAQ:CLNN) Posts Quarterly Earnings Results, Misses Expectations By $0.71 EPS

Clene (NASDAQ:CLNN) announced its earnings results on Friday. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.71), FiscalAI reports. The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.06 million.

Clene Stock Performance

Clene stock opened at $4.14 on Friday. The stock has a market cap of $52.91 million, a P/E ratio of -1.29 and a beta of 0.96. Clene has a fifty-two week low of $3.53 and a fifty-two week high of $13.50. The firm’s fifty day moving average price is $5.60 and its 200-day moving average price is $5.63.

Hedge Funds Weigh In On Clene

Several institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC purchased a new stake in Clene during the 2nd quarter valued at about $47,000. State Street Corp increased its stake in shares of Clene by 138.4% in the fourth quarter. State Street Corp now owns 29,801 shares of the company’s stock worth $175,000 after buying an additional 17,300 shares during the period. PEAK6 LLC purchased a new position in shares of Clene in the fourth quarter worth $294,000. Geode Capital Management LLC raised its holdings in Clene by 8.0% during the 4th quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock valued at $482,000 after buying an additional 6,090 shares during the last quarter. Finally, Scoggin Management LP raised its holdings in Clene by 42.7% during the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after buying an additional 42,750 shares during the last quarter. Institutional investors own 23.28% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. D. Boral Capital reiterated a “buy” rating and set a $23.00 price target on shares of Clene in a report on Monday, May 4th. Roth Capital reiterated a “buy” rating on shares of Clene in a research note on Thursday, May 14th. Weiss Ratings downgraded Clene from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 30th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $31.00 price target on shares of Clene in a research report on Monday, May 4th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.25.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).